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ABSTRACT
Despite established efficacy for cardiac implantable electrical devices (CIEDs), large differences in CIED implant rates have
been documented across and within countries. The aim of this paper is to investigate the influence of socio-economic, epide-
miological and supply side factors on CIED implant rates across 57 Regions in 5 EU countries and to assess the feasibility of
using administrative data for this purpose. A total of 1 330 098 hospitalizations for CIED procedures extracted from hospital
discharge databases in Austria, England, Germany, Italy and Slovenia from 2008 to 2012 was used in the analysis. Higher
levels of tertiary education among the labour force and percent of aged population are positively associated with implant rates
of CIED. Regional per capita GDP and number of implanting centres appear to have no significant effect. Institutional factors
are shown to be important for the diffusion of CIED. Wide variation in CIED implant rates across and within five EU
countries is undeniable. However, regional factors play a limited part in explaining these differences with few exceptions.
Administrative databases are a valuable source of data for investigating the diffusion of medical technologies, while the
choice of appropriate modelling strategy is crucial in identifying the drivers for variation across countries. © 2017 The
Authors. Health Economics published by John Wiley & Sons, Ltd.
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1. INTRODUCTION
Extensive empirical evidence shows that access to different types of medical technologies varies across
countries and within countries (Willeme & Dumont, 2015; Bech et al., 2009). Large differences in implant rates
have been documented for cardiac implantable electrical devices (CIEDs) despite their established and
internationally recognized efficacy for the management of arrhythmias (Valzania et al., 2015). Studies of trends
in CIED implants have shown rates consistently rising over time in virtually all countries. However, these
rising trends have not brought implant rates in various countries to similar levels, but quite contrarily, the
differences have persisted and, in some cases, even increased (Arribas et al., 2014; Valzania et al., 2015).
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The reasons for the great disparity in CIED implantation rates are not entirely known. Many factors are
presumed to be involved, and their relative contributions vary across the countries. A number of studies have
examined determinants of variation in CIED implant rates and in particular the impact of clinical guidelines
adoption and economic and organizational factors (Hatala et al., 2015). Available studies focused on different
types of CIED: pacemakers (PMs), implantable cardioverter defibrillators (ICDs) and cardiac resynchronization
therapy (CRT).
The majority of existing analysis investigated the issue at the country level and tested for correlations
between country-level socio-economic indicators and implant rates. For instance, Vardas and Ovsyscher
(2002) found significant differences among countries in PM implant rates and that first PM implants were
strongly correlated with gross domestic product (GDP) and the number of pacing centres. Ovsyshcher and
Furman (2003) found modest correlation between PM and ICD implant rates and economic (GDP and health
expenditures) and demographic factors, stressing the importance of comparing groups of patients of similar
age. In a study investigating ICD implants among European Society of Cardiology member nations, Lubinski
et al., 2015, found that implant rates per million inhabitants correlated with GDP, GDP per capita, health ex-
penditure, life expectancy and the number of implanting centres. Finally, Merkely et al. (2010)
investigated differences in implant rates of CRT devices and found that local reimbursement practices
and clinical guideline diffusion had some impact, but that GDP and healthcare spending did not greatly af-
fect implant rates.
Although a consensus on determinants of variation has not emerged as a result of comparison studies on PM
and ICD implant rates across nations, several nations have sought to investigate the reasons behind their lower
than expected implant rates in comparison with other countries (Lang, 2005). McComb et al. (2009) looked at
geographic variation in ICD implants among regions in the UK using data from public and private hospitals,
but through correlation analysis found no significant relationship between economic (deprivation index), health
(index for health), need (patients presenting with approved indications) or supply related (number of
cardiologists, implanting hospitals) factors to explain wide geographic variation observed within the UK and
low rates compared with other nations. A study in France using hospital discharge data linked with insurance
claims data highlighted large regional variation but did not perform statistical analysis to investigate the
determinants of such variation (Tuppin et al., 2011). A number of studies in the USA have looked at geographic
variation and hospital type, age, gender and race as factors potentially limiting access to PMs and ICDs
(El-Chami et al., 2007; Groeneveld et al., 2005; Scott et al., 2009).
In addition to a lack of conclusive empirical evidence on factors explaining variation, research up to
now has not provided a universal method for identifying determinants of diffusion of CIED that could
be of use in policymaking. The studies investigating differences among nations have relied on heteroge-
neous data sources, mostly registry or survey data, where differences in collection methods and a lack
of complete information for each country make results difficult to interpret. In addition, within-country
data on regional differences as well as demographic information on patients are often missing, limiting
interpretation of the results. Furthermore, the statistical techniques used to investigate determinants are
generally confined to a simple correlation analysis. A notable exception is the study by Bech et al. that
investigated the influence of economic incentives and regulatory factors on the adoption of treatment
technologies used to treat heart attacks, using unique patient-level data and solid econometric methods
(Bech et al., 2009).
To our knowledge, no studies so far have used individual records data based on hospital discharges nor
panel data regression techniques to empirically investigate the factors that influence diffusion of medical
technology in Europe.
Our objectives in undertaking the present study were to investigate the use of effective medical technology
in the field of electrophysiology to generate evidence on geographical variation and its determinants using a
reliable data source, a common protocol for extracting data and robust statistical methods for analyzing results.
More specifically, we have sought to produce evidence regarding differences in the use of CIED between and
within European member states using hospital discharge datasets available in five countries and to investigate
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the determinants of differences in access to these technologies to aid policymakers in determining where
intervention is needed. We additionally aimed to assess the potential and limitations of administrative databases
for the analysis of implant rates of these medical devices.
2. METHODS
2.1. Selection of technologies
The scope of our analysis is to investigate all types of CIED technologies available in the EU market that
include different devices: PMs, ICDs and, separately, the CRT subtypes of each of these devices (CRT-P
and CRT-D). Both ICDs and PMs continuously monitor cardiac rhythm. A PM is an implantable electrical
device able to deliver electrical impulses to regulate heart beating. An ICD is an implantable cardiac device that
continuously monitors cardiac rhythm and uses electrical pulses or shocks to help control life-threatening
arrhythmias, especially those that can cause sudden cardiac arrest. Thus, ICDs are more sophisticated
technologies than PMs because they can provide both pacing and anti-tachycardia therapies (anti-tachycardia
pacing and defibrillating shocks), while PMs can only provide pacing in the event of bradyarrhythmias.
Consequently, ICDs are more expensive than PMs because of their additional features and technology. CRT
is a stimulation technique based on right and left ventricular pacing, delivered by a PM (CRT-P) or a
cardioverter-ICD defibrillator (CRT-D) (Brignole et al., 2013; Priori et al., 2015). CRT is currently indicated
for some specific groups of chronic heart failure patients (Brignole et al., 2013).
Clinical guidelines represent a general recommendation for physiciansˈ decision-making in the choice of
which type of CIED is most appropriate. In routine clinical practice, indications for CIED are usually patient
tailored, taking into consideration age, general clinical status and comorbidities. Therefore, there is a certain
degree of discretion in physiciansˈ decision-making, which is related to the clinical context of the single patient
(i.e. the patientˈs arrhythmic events and structural heart disease).
In a first CIED implant, both generator and leads are implanted. After the first implant, replacement may be
needed and usually involves only the generator. The reasons leading to device replacement vary, although
battery depletion is the most common (after 5–10 years from the first implant). Device malfunction or infection
are less frequent events. Thus, factors affecting the implant rates for first implant and replacement may
substantially vary across different CIEDs. Given that the indications for the first implant and for replacement
are naturally diverse, there is a significant difference between them in terms of clinical and economic impact.
First implants are inherently more complicated procedures leading to higher complication rates, procedure costs
and length of stay.
2.2. Data sources and country selection
Hospital discharge record databases from 2008 to 2012 in Austria, England, Germany, Italy and Slovenia were
interrogated, and data regarding all hospitalizations associated with CIED implants and replacements were
extracted using direct cross-referencing of procedure codes from each countryˈs coding system. The device
types were identified as PMs, ICDs, CRT-Ps or CRT-Ds. Codes for removals, lead extractions, loop recorders,
temporary implantation or pocket revision were excluded.
The five countries were selected with the aim to capture, as much as possible, different European healthcare
systems across the following dimensions: (i) institutional set-up (national health system versus social health
insurance system); (ii) markets of different sizes; and (iii) level of decentralization. While these criteria allowed
us to define a larger pool of EU countries to be included in the analysis, our final choice was determined by the
existence of a nationally standardized list of procedure codes reflecting the choice of interventions and
feasibility of data access.
Exhaustive lists of procedural codes for implants and replacements of CIED were gathered from each
distinct coding system, compared and cross-referenced. A common protocol was developed to extract all
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hospital discharge records using the procedure code fields for the years 2008–2012 in all countries (data for
2012 were unavailable in England). Limited patient characteristics (residency, gender, age or age class and
comorbidities) and patient management measures (hospital code and location, length of stay and discharge
type) were available for each record (individual hospital codes were not available for Austria). Subsequent
common protocols were developed to aggregate data and form a central database by country and by region.
Regions were identified using the large regions classification (TL2) from OECD and Eurostat (Nuts 2) for a
total of 57 regions among the five countries (Austria – nine regions; England – nine regions; Germany –
16 regions; Italy – 21 regions; and Slovenia – two regions).
Crude implant rates per 100 000 inhabitants were calculated for each device and device subtype using the
aggregate database and regional and national population figures from the Eurostat website. Crude regional
implant rates per 100 000 inhabitants were also adjusted for gender and age by the direct standardization
method using the Revised European standard population, 2013. This adjustment was deemed necessary to
provide a meaningful comparison across countries in the descriptive analysis at the country level. Regional
socio-economic and organizational indicators for each year were gathered from OECD sources for GDP per
capita, the level of tertiary education expressed as a percentage of the total work force; and population density
expressed as the number of inhabitants per square kilometre. Eurostat sources were used for life expectancy at
birth in years, and the percentage of the population over 74 years of age was calculated from Eurostat
population figures (Eurostat, 2015).
2.3. Data analysis
A panel data regression model was designed to investigate drivers of variations in CIED implant rates across
and within 57 EU regions in the observation period 2008–2012. For all types of CIED technologies (PMs,
ICDs, CRT-PM and CRT-D), we estimate separate models for first implant and replacement rates using the
following:
yit ¼ βi þ βX it þ δT þ εit
The dependent variable (yit) in all models was the crude implant rate of one of four types of CIED (number
of implants/100 000 inhabitants at regional level). βi is the unobserved time-invariant regional effect; β is the
vector of time-variant parameters investigated, while δ is the vector of parameters for time effects. The model
tests the influence of economic and demographic factors (i.e. regional GDP per capita, percent of the resident
labour force with tertiary education, population density and percentage of patients over 74 years of age);
epidemiological (i.e. life expectancy) and supply side variables (i.e. number of implanting centres in the
region). Including dummies for each year allows our models to control for temporal variation in implant rates
across all regions. The error term εit in the model is a linear function of two components.
εit ¼ ζ i þ μit
The first component (the unobserved heterogeneity ζ i) represents the unobserved time-constant factors
shared between the five observation occasions on the same region that affect the implant rate (e.g. institutional
contexts). The second component (μit) is the unobserved time-varying factors, unique for each occasion t and
region i, and might include economic and health shocks. Assumptions about the error term determine whether
we apply fixed effects (FEs) or random effects (RE) estimators. Before choosing between RE and FE estima-
tion, we made several considerations. RE rely on the challenging assumption that unobserved heterogeneity is
uncorrelated with the regressors included in the model. Failure to meet such an assumption leads to inconsistent
estimates because of omitted variables. Given the great deal of potentially relevant information that is not
captured by the available set of regressors, this assumption is potentially critical in the present context. On
the other hand, the FE model may not perform well because we have little within subject variability (the CIED
implant rates do not change significantly over time as much as they change across regions). Furthermore, we
wish to estimate the effects of covariates that are virtually time-invariant in our time frame (i.e. number of
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hospitals in the region), and this is not possible with the FE estimator. Given the important advantages and
disadvantages of both models, we also performed the Hausman test for all models, to further inform our choice.
In addition to panel regression models on crude implant rates, we ran additional specifications on alternative
dependent variables: negative binomial on count data (number of implants), regression models on age and sex
adjusted implant rates as robustness checks for our findings (available as supplemental material). All statistical
analyzes were performed using the software package STATA 13.0 (StataCorp, College Station, TX, USA).
3. RESULTS
3.1. Descriptive statistics at country level
National hospital discharge databases were interrogated and information from 1 338 199 hospitalizations
associated with PM, and ICD procedures from 2008 to 2012 were gathered in country databases in Austria,
Germany, Italy and Slovenia, and from 2008 to 2011 in England. After excluding records with incomplete
information on patient residence and age class, the combined database consisted of 1 330 098 (99.4%) records,
1 017 441 associated with PM procedures and 312 657 associated with ICD procedures. On average, 211 531
PM and 62 132 ICD procedures/year were performed for the 204.5 million of EU residents, translating to crude
implant rates per 100 000 inhabitants of 103.5 for PMs and 30.4 for ICDs. Over the observation period, PM
implant rates rose from 97.9 to 108.4 per 100 000 inhabitants, and ICD implant rates rose from 25.7 to 34.2
for the five countries combined.
Overall, the average length of stay (excluding outliers at the 99th percentile) was 8.72 and 3.75, respectively,
for first implants and replacements of PMs, and 9.85 and 4.55, respectively, for first implants and replacements
of ICDs. More specifically, the average length of stay for PM first implants ranged from 6.09 days in Slovenia
to 10.43 days in Germany, while average hospital stay for PM replacement was significantly shorter (ranging
from 2.54 days in England to 4.25 days in Austria). The same pattern was observed for ICDs (7.04 days in En-
gland and 11.23 days in Slovenia, respectively, for first implants and 3.49 days in England and 7.13 days in
Slovenia, respectively, for replacements).
Table I illustrates crude and standardized first implant and replacement rates per 100 000 inhabitants for the
four types of CIED in each of the five countries across the study period. England and Germany registered the
greatest changes over time in first implant rates of PMs, although replacement rates remained fairly stable. ICD
implant rates have risen over the study period in all countries but marked differences in rates between countries
remained with England and Slovenia showing significantly lower values compared with other countries.
Germany registered the highest implant rates for almost all types of technologies.
Codes were available for discerning CRT devices in all countries except Slovenia, and because of the
extension of clinical indications for CRT-P and CRT-D in recent years, these technologies were analyzed
separately. Crude first implant and replacement rates have increased over the period for CRT-P (+54% in
Austria, +49% in England and nearly doubling in Germany and Italy) and particularly for CRT-D (+64% in
Austria, +89% in Germany, +143% in Italy and increased more than 10-fold in England).
All independent variables across five countries are displayed in Table I. Unfortunately, the number of
implanting centres was not available for Austria at the time of the analysis.
3.2. Model estimation at regional level
The 57 regions in the datasets showed considerable variation in first implant and replacement rates per 100 000
inhabitants for all types of CIED, especially for PMs. For ICDs, crude and adjusted implant rates exhibited
large differences across regions in Germany and Italy, and a more contained range of values for Austria.
England showed much less variation in implant rates in comparison with all countries except Slovenia
(with only two regions). The largest differences among regions were observed for crude and adjusted implant
rates for CRT-P and CRT-D devices.
A. TORBICA ET AL.34
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The potential drivers of these differences were investigated in a series of panel regression models. Hausman
test confirmed consistency of RE estimation for the majority of the models, but not for all. Based on this test
result, and in addition to the reasons outlined earlier, we refrained from estimating only RE models in order
to provide consistent estimates of the parameters. We adopt a more conservative approach and run both
specifications of the models (FE and RE) and discuss the results. Tables II–V display the results of all models
across four different types of CIED (PMs, ICDs, CRT-P and CRT-D, respectively).
The percentage of population with tertiary education among the labour force of the regions had a positive
impact on PM first implants (both FE and RE model) and replacements (only in RE). The percentage of
population over 74 appears to have a positive impact on both first and replacement PM rates but only in the
RE model. GDP per capita has counterintuitive negative signs for both first and replacement PM implant rates
(but the result is significant only in the RE model). The time trends did not have any significant impact on the
first implant rates of PMs across regions nor did the number of implanting centres. On the other hand,
country effect was strong in all RE models, suggesting strong influence of time-invariant factors captured at
the country level.
The findings for ICD implant rates suggest slightly different insights (Table III). Population over 74 years
had a significant positive effect across all specifications, while tertiary education had positive effects only for
first ICD implants. We found no significant effect for per capita GDP across all models. The number of
implanting hospitals did not have a significant impact on ICD implant rates either. Interestingly, the time trend
was very strong for both first implant (only in RE) and replacement ICD rates (both FE and RE), that is,
Table II. Determinants of diffusion of PM across EU regions 2008–2012 (first implants and replacements)









Slovenia (dummy) 0.000 (.)
England 36.044*** (9.642) 0.000 (.)
Germany 67.221*** (9.765) 7.412** (2.525)
Italy 47.321*** (11.842) 12.112** (3.777)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.318 (2.029) 0.194 (1.337) 0.795 (0.792) 0.215 (0.529)
2010 0.904 (2.386) 1.117 (1.619) 0.238 (0.924) 0.693 (0.648)
2011 1.880 (3.124) 2.396 (2.030) 1.639 (1.205) 2.019* (0.825)
2012 0.344 (3.979) 0.320 (2.354) 1.213 (1.526) 1.705 (0.961)
GDP per capita
(1000s)
0.133 (0.771) 0.674** (0.260) 0.084 (0.303) 0.338** (0.111)
Tertiary education 1.290** (0.479) 1.583*** (0.378) 0.105 (0.190) 0.376* (0.154)
Population density 0.012 (0.035) 0.007* (0.003) 0.002 (0.013) 0.001 (0.001)
Population over 74 1.747 (2.891) 3.098* (1.385) 0.798 (1.094) 1.248* (0.578)
Life expectancy 4.186 (2.444) 1.311 (1.775) 1.115 (0.934) 0.511 (0.726)
Number of
implanting centres
0.209 (0.142) 0.002 (0.042) 0.077 (0.053) 0.013 (0.018)
_cons 316.933 (199.060) 121.133 (137.602) 70.408 (75.994) 34.417 (57.103)
N 231 231 221 221
r2_within 0.374 0.359 0.106 0.079
r2_between 0.003 0.730 0.003 0.600
r2_overall 0.013 0.706 0.005 0.556
Rho (ICC)a 0.961 0.816 0.948 0.858
FE, fixed effect; RE, random effect; PM, pacemaker; GDP, gross domestic product.
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parameters were positive and significant for almost all years, suggesting the importance of some common
trends across EU regions. Country effect was significant for Italy and Germany for ICD first implants, and
Germany and England for replacements.
Models for CRT-P and CRT-D further confirm the importance of time trends across EU regions, but to
a lesser extent (Tables IV and V). It is worth noting that for these two categories of devices we had fewer
observations because not all countries had available codes for CRT-D and CRT-P devices for both first
implants and replacements. In addition, the overall rate of CRT-P was affected by the level of tertiary
education among the labour force only in one model specification, while the number of implanting
hospitals resulted non-significant. Population over 74 resulted positive and significant only for CRT-Ds.
Population density had a weak effect, and per capita GDP was not significant across models for both
device categories.
4. DISCUSSION
A steady increase in CIED has been observed in Europe over the last decades as a consequence of the results of
large clinical trials, the development of scientific guidelines and the implementation of knowledge in clinical
practice. With the increase in clinical indications and cardiac pacing practice, there has been growing interest
in investigating access to CIED across countries. Available evidence shows that there is significant heterogene-
ity in implant rates of CIED across and between countries, while few studies have empirically investigated the
Table III. Determinants of diffusion of ICDs across 57 EU regions 2008–2012 (first implants and replacements)









Slovenia (dummy) 0.000 (.) 0.000 (.)
England 0.652 (5.068) 3.148* (1.586)
Germany 26.726*** (5.136) 7.133*** (1.611)
Italy 23.173*** (6.275) 3.788 (2.037)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.713 (1.020) 0.846 (0.723) 1.807*** (0.392) 1.400*** (0.258)
2010 1.160 (1.200) 2.982*** (0.872) 3.000*** (0.461) 2.806*** (0.305)
2011 0.772 (1.570) 4.276*** (1.090) 3.492*** (0.603) 3.438*** (0.375)
2012 1.032 (2.000) 4.486*** (1.261) 3.726*** (0.768) 3.895*** (0.429)
GDP per capita
(1000s)
0.246 (0.387) 0.185 (0.138) 0.183 (0.149) 0.048 (0.044)
Tertiary education 0.551* (0.241) 0.726*** (0.204) 0.212* (0.092) 0.042 (0.071)
Population density 0.012 (0.018) 0.001 (0.002) 0.002 (0.007) 0.000 (0.000)
Population over 74 7.816*** (1.453) 2.175** (0.735) 1.469** (0.558) 0.785** (0.239)
Life expectancy 1.413 (1.228) 2.631** (0.952) 0.131 (0.472) 0.259 (0.325)
Number of
implanting centres
0.063 (0.071) 0.003 (0.022) 0.004 (0.027) 0.005 (0.007)
_cons 42.611 (100.056) 185.227* (73.752) 1.575 (38.413) 15.773 (25.052)
N 231 231 231 231
r2_within 0.536 0.457 0.748 0.730
r2_between 0.000 0.749 0.072 0.628
r2_overall 0.003 0.713 0.122 0.645
Rho (ICC)a 0.978 0.805 0.946 0.744
FE, fixed effect; RE, random effect; ICDs, implantable cardioverter defibrillators; GDP, gross domestic product.
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factors that might influence these implant rates in Europe by employing comprehensive databases and robust
statistical methods.
Our study is the first empirical analysis to use national, hospital discharge datasets to investigate
variation in implant rates of CIED across EU countries at the regional level. Although methodologies
employed in our analysis are rather different from those used in previous studies, our findings partially
confirm previous results. More specifically, the portion of residents over 74 years of age is significantly
and positively associated with implant rates for ICDs and CRT-Ds, similar to the analysis on western
European countries and the USA (Ovsyshcher & Furman, 2003). However, the number of implanting
centres was identified as an important factor for diffusion of CIED in several studies (Lubinski et al.,
2011; Merkely et al., 2010; Wolpert et al., 2011), which has not been confirmed in our investigation.
In our analysis, the level of tertiary education among the regional labour force showed positive association
with implant rates in almost all models. This result might suggest that regions where levels of education
are generally higher play an important role in access to innovative medical technologies. Indeed, the lower
levels of educational attainment have been put forward by Camm and Nisam (2010) among potential
explanatory factors for significantly lower rates of ICDs in Europe versus the USA. The authors argue that
in Europe (differently from the USA) neither the patients nor their relatives and friends are usually well
informed about medical opportunities in the field, suggesting that education may affect access to highly
specialized care (Camm & Nisam, 2000; 2010. Our study is the first European investigation that gives
further insights into this important issue on the role of education and access to medical technologies
and warrants further research.
Table IV. Determinants of diffusion of cardiac resynchronization therapies (CRT-P) across 57 EU regions 2008–2012
(CRT-P)









England (dummy) 0.000 (.)
Germany 1.713*** (0.463) 0.000 (.)
Italy 0.926 (0.844) 0.339 (0.504)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.202 (0.243) 0.152 (0.157) 0.120 (0.159) 0.041 (0.112)
2010 0.757** (0.283) 0.701*** (0.178) 0.140 (0.177) 0.226 (0.125)
2011 0.984** (0.362) 0.900*** (0.209) 0.256 (0.223) 0.304* (0.145)
2012 1.170* (0.453) 1.007*** (0.233) 0.302 (0.278) 0.351* (0.162)
GDP per capita
(1000s)
0.048 (0.086) 0.035 (0.021) 0.109 (0.057) 0.007 (0.015)
Tertiary education 0.067 (0.061) 0.080* (0.039) 0.082 (0.050) 0.011 (0.030)
Population density 0.005 (0.004) 0.001* (0.000) 0.001 (0.003) -0.000 (0.000)
Population over 74 0.171 (0.307) 0.079 (0.110) 0.092 (0.201) 0.031 (0.077)
Life expectancy 0.004 (0.265) 0.194 (0.159) 0.074 (0.186) 0.038 (0.124)
Number of
implanting centres
0.011 (0.015) 0.001 (0.003) 0.001 (0.010) 0.002 (0.002)
_cons 2.479 (21.346) 14.970 (12.340) 2.406 (14.841) 3.334 (9.606)
N 199 199 161 161
r2_within 0.455 0.442 0.293 0.250
r2_between 0.000 0.545 0.001 0.224
r2_overall 0.004 0.511 0.004 0.233
Rho (ICC)a 0.985 0.700 0.961 0.751
FE, fixed effect; RE, random effect; GDP, gross domestic product.
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Our study only partially confirms the results of previous investigations showing the importance of economic
factors for the diffusion of CIED. More specifically, Ovsyscher and Furman showed a significant, although
modest, correlation between economic indices such as GNP and per capita annual health expenditures with Eu-
ropean first time PM (r=0.61, p<0.01) and ICD implant rates (0.66, p<0.01) (Ovsyscher & Furman, 2003).
The correlation is modest because some countries with similar economic indices have significantly different im-
plant rates. For example, the Czech Republic, with a considerably lower economic status, has much higher PM
and ICD implant rates than the UK, which in turn was most likely influenced by rather restrictive NICE guide-
lines. Merkely et al. (2010) argue that, while countries with higher GDP or healthcare spending per capita gen-
erally had a higher number of CRT implantations, because of large variations, the correlation between these
factors and the number of CRT implantations was weak. In our study, regional per capita GDP did not have
any impact on CIED implant rates in any of the FE models. It resulted significant only in RE models investi-
gating the implant rate of PMs, with a counterintuitive negative sign. We believe that this result highlights the
importance of appropriate model estimation in order to obtain consistent parameter estimates.
More importantly than partially confirming the results of previous studies, our study brings in relevant
methodological advancements to the literature investigating the variations in medical device implant rates
across countries. Moreover, our analysis is the first cross-country investigation of factors driving CIED
utilization rates at regional levels. The methodology employed is innovative in two aspects: the data sources
used and statistical methods employed. As a data source, considerable effort has been made to assess and
test the potential and reliability of using national hospital discharge records to study diffusion of CIED.
Hospital discharge databases have a great advantage over other sources of data (i.e. registries) because they
ensure national coverage and are completed according to standardized methods. Other data sources often
Table V. Determinants of diffusion of cardiac resynchronization therapies across 57 EU regions 2008–2012 (CRT-D)









England (dummy) 0.000 (.)
Germany 8.457*** (1.520) 0.000 (.)
Italy 1.449 (2.637) 2.189 (1.189)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.630 (0.620) 1.371** (0.445) 0.372 (0.382) 0.414 (0.266)
2010 2.229** (0.729) 3.635*** (0.518) 1.414** (0.425) 1.394*** (0.295)
2011 2.231* (0.935) 4.380*** (0.623) 1.948*** (0.536) 1.856*** (0.344)
2012 1.327 (1.169) 4.470*** (0.703) 2.500*** (0.667) 2.382*** (0.383)
GDP per capita
(1000s)
0.270 (0.218) 0.108 (0.068) 0.188 (0.130) -0.045 (0.034)
Tertiary education 0.001 (0.157) 0.104 (0.118) 0.141 (0.116) 0.037 (0.071)
Population density 0.004 (0.009) 0.000 (0.001) 0.001 (0.007) 0.000 (0.000)
Population over 74 3.963*** (0.788) 1.092** (0.356) 0.429 (0.484) 0.330 (0.181)
Life expectancy 0.773 (0.681) 0.095 (0.491) 0.506 (0.448) 0.281 (0.294)
Number of implanting
centres
0.014 (0.039) 0.000 (0.010) 0.040 (0.023) 0.001 (0.005)
_cons 87.807 (54.913) 0.722 (38.113) 37.258 (35.578) 21.224 (22.804)
N 200 200 164 164
r2_within 0.741 0.709 0.690 0.673
r2_between 0.008 0.635 0.000 0.125
r2_overall 0.031 0.657 0.040 0.378
Rho (ICC)a 0.966 0.789 0.930 0.737
FE, fixed effect; RE, random effect; GDP, gross domestic product.
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come from registry or survey data, which can mean significant variation in data collection methods, quality
and completeness, inconsistent reporting of specific device types and an absence of patient and clinical in-
formation. By leveraging on this great potential, we developed a common protocol to identify diagnostic
and procedure codes across countries using different coding systems. We believe that the study reported
here provides a compelling argument for the use of hospital discharge data to analyze trends in implant
rates and clinical practices for selected MDs. Further analysis is encouraged to expand use of administrative
data for other technologies and to more closely monitor differences among regions and hospitals within
countries.
Regarding the methods applied for data analysis, our study is considerably different from the current
empirical studies that analyzed geographical variations in CIED implantation. All other studies relied on
relatively simple statistical methods to test correlation between utilization rates and potential explanatory
variables (i.e. Spearmanˈs correlation test). Merkely et al. (2010) used stepwise multiple regression analysis
to identify independent factors that affect the number of CRT implantations per capita. These methods have
considerable drawbacks and fall short in explaining the actual impact of selected covariates on the outcome
variable. Our analysis is the first to use panel data regression methods, using both RE and FE estimation
models, to investigate within (temporal) and between (geographical) variations of CIED utilization rates in
57 European regions. Our results shed light on the importance of appropriate model estimation. A different
choice of empirical model may lead to different findings that could translate to diverse policy
recommendations. The FE estimator provides the most consistent parameter estimates in the context in which
the likelihood of omitted variable bias is very high, which is particularly relevant in international comparative
studies. However, its estimation may pose several challenges.
4.1. Study limitations
The present study is based on the use of administrative data for exploring implant rates but did not
assess outcome, as was carried out in other studies using hospital discharge data (Ghislandi et al.,
2013). The accuracy of the administrative data that we consider can be variable, for complex reasons that
cannot be analyzed in depth. With this regard, one of the sources of data may have a higher degree of
approximation, as we reported. Furthermore, it should be noted that we were able to include only a
limited set of independent variables because the data at the regional level are not readily available.
For example, other variables such as the education level of physicians and their attitudes toward specific
devices may play an important role in explaining differences in implant rates of these technologies.
Finally, we did not discuss an optimal or appropriate CIED implant rate in our paper. All of these issues
should be investigated in further research efforts aimed to uncover drivers of differences in implant rates
of CIED across countries.
5. CONCLUSIONS
The implant rates of CIED are a very relevant policy topic for investigation because these devices represent
compelling examples of health technologies that have been proven to remarkably improve health outcomes
of populations while, at the same time, increasing barriers that prevent their full diffusion into clinical practice.
Given the epidemiological and demographic trends, it is essential that policymakers search for explanations for
the observed variations. Timely and comprehensive data reporting is necessary to keep abreast of the situation,
and administrative databases are a valid and reliable source to investigate the issue at national and international
levels. We believe that these methods could be implemented for further analyses on determinants of medical
device diffusion and possibly extended to additional databases collecting administrative health information
within an international, national or regional context.
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APPENDIX A: REGRESSION MODELS WITH AGE-STANDARDIZED AND SEX-STANDARDIZED
IMPLANT RATES AS DEPENDENT VARIABLES
Table AI. Determinants of diffusion of PM across EU regions 2008–2012 (first implants and replacements)









Slovenia (dummy) 0.000 (.)
England 40.162*** (9.144) 0.000 (.)
Germany 65.389*** (9.275) 5.634* (2.393)
Italy 53.296*** (11.477) 12.310*** (3.604)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.006 (2.102) 0.459 (1.368) 0.660 (0.759) 0.167 (0.508)
2010 0.449 (2.472) 0.488 (1.640) -0.447 (0.886) 0.748 (0.622)
2011 1.789 (3.236) 1.897 (2.038) 1.832 (1.155) 1.971* (0.790)
2012 0.586 (4.121) 0.380 (2.347) 1.472 (1.463) 1.620 (0.918)
GDP per capita
(1000s)
0.229 (0.798) 0.681** (0.252) 0.104 (0.290) 0.334** (0.106)
Tertiary education 1.480** (0.496) 1.732*** (0.383) 0.059 (0.183) 0.341* (0.148)
Population density 0.031 (0.037) 0.006* (0.003) 0.002 (0.013) 0.001 (0.001)
Population over 74 6.056* (2.994) 3.255* (1.346) 0.922 (1.049) 0.748 (0.550)
Life expectancy 5.341* (2.531) 2.309 (1.776) 1.410 (0.895) 0.699 (0.696)
Number of
implanting centres
0.212 (0.147) 0.017 (0.040) 0.079 (0.051) 0.021 (0.017)
_cons 346.449 (206.178) 147.739 (137.350) 76.508 (72.847) 30.135 (54.654)
N 231 231 221 221
r2_within 0.267 0.245 0.192 0.160
r2_between 0.044 0.671 0.023 0.501
r2_overall 0.048 0.642 0.012 0.470
Rho (ICC)a 0.982 0.784 0.951 0.853
FE, fixed effect; PM, pacemaker; RE, random effect; GDP, gross domestic product.
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Table AII. Determinants of diffusion of ICDs across 57 EU regions 2008–2012 (first implants and replacements)









Slovenia (dummy) 0.000 (.) 0.000 (.)
England 1.259 (4.863) 3.387* (1.494)
Germany 26.297*** (4.933) 6.444*** (1.518)
Italy 26.405*** (6.118) 4.304* (1.940)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.363 (1.056) 0.590 (0.734) 2.045*** (0.388) 1.324*** (0.253)
2010 0.914 (1.242) 2.760** (0.879) 3.289*** (0.457) 2.678*** (0.298)
2011 0.600 (1.626) 4.115*** (1.091) 3.911*** (0.598) 3.291*** (0.364)
2012 1.387 (2.070) 4.214*** (1.255) 4.460*** (0.761) 3.825*** (0.414)
GDP per capita
(1000s)
0.130 (0.401) 0.224 (0.134) 0.288 (0.147) 0.052 (0.042)
Tertiary education 0.584* (0.249) 0.750*** (0.205) 0.270** (0.092) 0.044 (0.069)
Population density 0.018 (0.018) 0.001 (0.002) 0.007 (0.007) 0.001 (0.000)
Population over 74 6.559*** (1.504) 0.666 (0.718) 0.423 (0.553) 0.326 (0.227)
Life expectancy 1.267 (1.272) 2.164* (0.950) 0.025 (0.468) 0.020 (0.313)
Number of
implanting centres
0.080 (0.074) 0.016 (0.021) 0.008 (0.027) 0.011 (0.007)
_cons 44.013 (103.573) 160.774* (73.448) 7.671 (38.089) 2.654 (24.135)
N 231 231 231 231
r2_within 0.438 0.344 0.726 0.706
r2_between 0.004 0.739 0.003 0.566
r2_overall 0.001 0.693 0.019 0.600
Rho (ICC)a 0.983 0.780 0.982 0.724
FE, fixed effect, ICDs, implantable cardioverter defibrillators; RE, random effect; GDP, gross domestic product.
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Table AIII. Determinants of diffusion of cardiac resynchronization therapies (CRT-P) across 57 EU regions 2008–2012
(CRT-P)









England (dummy) 0.000 (.)
Germany 2.461*** (0.499) 0.000 (.)
Italy 1.133 (0.910) 0.648 (0.519)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.266 (0.263) 0.166 (0.169) 0.067 (0.161) 0.023 (0.115)
2010 0.785* (0.306) 0.705*** (0.192) 0.235 (0.179) 0.192 (0.127)
2011 0.968* (0.392) 0.874*** (0.226) 0.367 (0.226) 0.257 (0.148)
2012 1.110* (0.490) 0.928*** (0.252) 0.510 (0.281) 0.331* (0.165)
GDP per capita
(1000s)
0.088 (0.093) 0.040 (0.022) 0.037 (0.058) 0.020 (0.015)
Tertiary education 0.080 (0.066) 0.097* (0.042) 0.080 (0.052) 0.010 (0.032)
Population density 0.005 (0.004) 0.000 (0.000) 0.001 (0.003) 0.000 (0.000)
Population over 74 0.362 (0.332) 0.065 (0.118) 0.413 (0.209) 0.052 (0.079)
Life expectancy 0.058 (0.286) 0.174 (0.172) 0.043 (0.189) 0.020 (0.126)
Number of
implanting centres
0.010 (0.016) 0.000 (0.003) 0.002 (0.010) 0.002 (0.002)
_cons 2.188 (23.099) 14.519 (13.308) 0.970 (15.044) 1.719 (9.784)
N 199 199 160 160
r2_within 0.372 0.359 0.229 0.181
r2_between 0.005 0.668 0.053 0.238
r2_overall 0.000 0.610 0.026 0.232
Rho (ICC)a 0.982 0.698 0.931 0.754
FE, fixed effect, RE, random effect, GDP, gross domestic product.





REGIONAL VARIATIONS IN MEDICAL DEVICE DIFFUSION 43
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 30–45 (2017)
DOI: 10.1002/hec
ACKNOWLEDGEMENTS
The authors gratefully thank the Italian Ministry of Health for providing data from the Italian National Hospital
Discharge Database (http://www.salute.gov.it/portale/temi/p2_4.jsp?area=ricoveriOspedalieri) for this study.
REFERENCES
Arribas F, Auricchio A, Boriani G, Brugada J, Deharo JC, Hindriks G, et al. 2014. Statistics on the use of cardiac electronic
devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm
Association (EHRA). Europace 16(Suppl 1): i1–78.
Bech M, Christiansen T, Dunham K, Lauridsen J, Lyttkens CH, Mcdonald K, et al. 2009. The influence of economic
incentives and regulatory factors on the adoption of treatment technologies: a case study of technologies used to treat
heart attacks. Health Economics 18: 1114–32.
Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O, et al. 2013. ESC Guidelines on cardiac
pacing and cardiac resynchronization therapy. European Heart Journal 34(29): 2281–2329.
Camm A, Nisam S. 2010. European utilization of the implantable defibrillator: has 10 years changed the ‘enigma’?
Europace 12: 1063–9.
Camm AJ, Nisam S. 2000. The utilization of the implantable defibrillator—a European enigma. European Heart Journal
21: 1998–2004.
El-Chami MF, Hanna IR, Bush H, Langberg JJ. 2007. Impact of race and gender on cardiac device implantations. Heart
Rhythm 4: 1420–6.
Eurostat 2015. Life expectancy at birth by sex and NUTS 2 region. (http://ec.europa.eu/eurostat/tgm/table.do?
tab=table&plugin=1&language=en&pcode=tgs00101 Accessed on February 2016)
Table AIV. Determinants of diffusion of cardiac resynchronization therapies across 57 EU regions 2008–2012 (CRT-D)









England (dummy) 0.000 (.)
Germany 8.568*** (1.477) 0.000 (.)
Italy 2.617 (2.615) 1.554 (1.189)
2008 (dummy) 0.000 (.) 0.000 (.) 0.000 (.) 0.000 (.)
2009 0.483 (0.658) 1.108* (0.456) 0.323 (0.399) 0.231 (0.276)
2010 2.244** (0.774) 3.420*** (0.526) 1.404** (0.443) 1.193*** (0.304)
2011 2.394* (0.993) 4.197*** (0.627) 2.041*** (0.559) 1.682*** (0.352)
2012 1.571 (1.241) 4.192*** (0.704) 2.699*** (0.696) 2.205*** (0.389)
GDP per capita
(1000s)
0.307 (0.231) 0.131* (0.066) 0.158 (0.136) 0.037 (0.034)
Tertiary education 0.013 (0.167) 0.140 (0.118) 0.146 (0.121) 0.031 (0.072)
Population density 0.011 (0.010) 0.000 (0.001) 0.006 (0.007) 0.000 (0.000)
Population over 74 2.863*** (0.836) 0.405 (0.348) 0.133 (0.505) 0.124 (0.179)
Life expectancy 1.159 (0.723) 0.341 (0.490) 0.646 (0.467) 0.389 (0.295)
Number of
implanting centres
0.005 (0.041) 0.002 (0.010) 0.037 (0.024) 0.002 (0.005)
_cons 110.857 (58.304) 30.202 (37.967) 46.149 (37.114) 28.759 (22.931)
N 200 200 164 164
r2_within 0.697 0.671 0.646 0.625
r2_between 0.002 0.611 0.022 0.028
r2_overall 0.001 0.632 0.000 0.312
Rho (ICC)a 0.976 0.759 0.962 0.708
FE, fixed effect; RE, random effect; GDP, gross domestic product.





A. TORBICA ET AL.44
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 30–45 (2017)
DOI: 10.1002/hec
Ghislandi S, Torbica A, Boriani G. 2013. Assessing the outcomes of implantable cardioverter defibrillator treatment in a real
world setting: results from hospital record data. BMC Health Services Research 13: 100.
Groeneveld PW, Heidenreich PA, Garber AM. 2005. Trends in implantable cardioverter-defibrillator racial disparity: the
importance of geography. Journal of the American College of Cardiology 45: 72–8.
Hatala R, Lunati M, Calvi V, Favale S, Goncalvesova E, Haim M, et al. 2015. Clinical implementation of cardiac
resynchronization therapy-regional disparities across selected ESC member countries. Annals of Noninvasive
Electrocardiology 20: 43–52.
Lang CC. 2005. Regional variation in ICD implantation rates: the shocking truth? Heart 91: 1251–3.
Lubinski A, Bissinger A, Boersma L, Leenhardt A, Merkely B, Oto A, et al. 2011. Determinants of geographic variations in
implantation of cardiac defibrillators in the European Society of Cardiology member countries—data from the European
Heart Rhythm Association White Book. Europace 13: 654–62.
Mccomb JM, Plummer CJ, Cunningham MW, Cunningham D. 2009. Inequity of access to implantable cardioverter
defibrillator therapy in England: possible causes of geographical variation in implantation rates. Europace 11: 1308–12.
Merkely B, Roka A, Kutyifa V, Boersma L, Leenhardt A, Lubinski A, et al. 2010. Tracing the European course of cardiac
resynchronization therapy from 2006 to 2008. Europace 12: 692–701.
Ovsyshcher IE, Furman S. 2003. Determinants of geographic variations in pacemakers and implantable cardioverter
defibrillators implantation rates. Pacing and Clinical Electrophysiology 26: 474–8.
Priori S, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015. ESC Guidelines for the man-
agement of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal
Aug 2015, ehv316; DOI: 10.1093/eurheartj/ehv316.
Scott PA, Turner NG, Chungh A, Morgan JM, Roberts PR. 2009. Varying implantable cardioverter defibrillator referral
patterns from implanting and non-implanting hospitals. Europace 11: 1048–51.
Tuppin P, Neumann A, Marijon E, De Peretti C, Weill A, Ricordeau P, et al. 2011. Implantation and patient profiles for
pacemakers and cardioverter-defibrillators in France (2008–2009). Archives of Cardiovascular Diseases 104: 332–42.
Valzania, C., Torbica, A., Tarricone, R., Leyva, F., Boriani, G. 2015. Implant rates of cardiac implantable electrical devices
in Europe: a systematic literature review. Health Policy.
Vardas PE, Ovsyscher EI. 2002. Geographic differences of pacemaker implant rates in Europe. Journal of Cardiovascular
Electrophysiology 13: S23–6.
Willeme P, Dumont M. 2015. Machines that go ‘Ping’: medical technology and health expenditures in OECD countries.
Health Economics 24: 1027–41.
Wolpert C, Lubinski A, Bissinger A, Merkely B, Priori S, Brugada J. 2011. Barriers to implementation of evidence-based
electrical therapies and the need for outcome research: role of European registries. Europace 13(Suppl 2): ii18–20.
REGIONAL VARIATIONS IN MEDICAL DEVICE DIFFUSION 45
© 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd. Health Econ. 26(Suppl. 1): 30–45 (2017)
DOI: 10.1002/hec
